Identifying brain recovery markers in stroke patients with aphasia
Genetic and MRI Biomarkers of Neuroplasticity Predict Aphasia Recovery and Phenotypes
This study is trying to find out how brain recovery affects language skills in stroke patients with aphasia to help improve their treatment and recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06471127 on ClinicalTrials.gov |
What this trial studies
This research focuses on understanding how neuroplasticity affects recovery from aphasia in stroke patients. It aims to evaluate genetic and neural network biomarkers associated with individual differences in recovery outcomes. The study will track changes in language abilities over time and identify predictors of chronic aphasia severity and learning variability. By doing so, it seeks to enhance prognostic models and inform targeted rehabilitation strategies for those affected by aphasia.
Who should consider this trial
Good fit: Ideal candidates are right-handed, proficient English-speaking adults aged 40-90 who have experienced a single ischemic stroke and currently exhibit aphasia.
Not a fit: Patients with significant medical or neurological disorders, poorly controlled psychiatric conditions, or those with uncorrected vision or hearing loss may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and personalized rehabilitation therapies for stroke survivors with aphasia.
How similar studies have performed: Other studies have shown promise in using neuroplasticity markers for recovery prediction in stroke patients, indicating that this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ages 40-90 2. Right-handed (prior to stroke) 3. Proficient English speakers 4. History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere. 5. Presence of aphasia (Aims 2-3) 6. Capacity to understand the nature of the study and provide informed consent 7. Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment 8. Medically stable Exclusion Criteria: 1. History of significant medical or neurological disorder (other than stroke) 2. History of significant or poorly controlled psychiatric disorders 3. Current abuse of alcohol or drugs, prescription or otherwise 4. Clinically significant and uncorrected vision or hearing loss 5. Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin
Where this trial is running
Madison, Wisconsin
- UW School of Medicine and Public Health — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Haley Dresang, PhD — University of Wisconsin, Madison
- Study coordinator: Haley Dresang, PhD
- Email: hdresang@wisc.edu
- Phone: (608) 890-0628
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.